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Abstract: The recent proliferation of probiotics in supermarkets, drugstores and on the
Internet requires consideration of their unique properties in establishing an appropriate
framework for their regulation. Although a separate regulatory category at the Food and
Drug Administration is not justified, certain reforms should be considered to achieve
more efficient regulation and greater reliability on probiotic product claims.
Main Text:
Initial findings of the Human Microbiome Project (HMP), an NIH Common Fund
initiative, to characterize the microorganisms that live in and on the human body and
analyze their role in health and disease, were published a little over a year ago (1).
While the findings raise more questions than they answer about the role and variation
of microorganisms within individuals and across populations, they have already begun
to promote the development of probiotics, substances containing live microorganisms
1

that have a beneficial effect when taken in sufficient quantities (2) and “designed to
intentionally manipulate microbiome and host properties”(3). The findings will also
provide a “baseline” by which to measure changes in an individual’s microbiome
produced by the consumption of probiotic products.
Most probiotics currently on the market are sold as foods or dietary supplements.
Probiotics have been consumed for centuries in the form of yogurts and fermented
milks. In recent years the variety of probiotic foods on supermarket shelves has
significantly expanded, and probiotic dietary supplements are being aggressively
marketed in retail stores and on the Internet. Although no probiotic has been approved
for therapeutic purposes, a number are undergoing clinical trials and may soon be
marketed as biologics or other drugs (4). There is already a body of published evidence
of the potential benefit of some strains and species of probiotics for a variety of
indications (5).
In addition to promoting the development of novel clinical therapies, the HMP is likely
to increase the number of probiotic foods and dietary supplements available to
consumers as well as the claims made about them (6). Consumer demand for these
products is growing in large part because of their health and wellness claims (7). Reid et
al. (8) and others (9) have asserted that while some of these claims may have merit,
others do not. Many probiotics have not been adequately tested for efficacy yet “make
claims that lead consumers . . . to believe that they are using reliable products”(8).
One of the goals of the HMP was to study the ethical, legal and social issues (ELSI) raised
by human microbiome research. One such issue is whether the current regulatory
framework for probiotics: 1) adequately addresses issues of safety and effectiveness; 2)
provides sufficient information to consumers to make informed choices about
purchasing probiotic products; and 3) sufficiently allows for, or at least does not
discourage, research on the potential therapeutic benefits of probiotics. These
questions were addressed as part of an NIH HMP-funded ELSI study which brought
together a Working Group (WG) of human microbiome researchers, legal academics,
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food and drug law attorneys, consumer advocates, bioethicists, industry
representatives, an official from the US Federal Trade Commission (FTC) and a
representative from Health Canada’s Natural Health Products Directorate (10).
(Although officials from the US Food and Drug Administration (FDA) were invited to
participate as members of the WG, they declined to do so because of the perceived
problem of a conflict of interest arising from a project that might result in
recommendations to change the FDA’s approach to regulating probiotics (11)). This
article reports on several of the WG’s observations about the regulatory process for
probiotics and potential areas for reform.
To date, FDA’s approach to probiotic products has relied entirely on its existing
regulatory framework. That is, FDA has no definition of probiotics and regulates them
based on whether they fall into one of the existing regulated product categories (12),
i.e., drugs, biologics, foods, food additives, medical foods, foods for special dietary use,
dietary supplements, medical devices, or cosmetics. (See Table 1.) Because probiotics
fall into multiple categories, expertise about them is spread unevenly across multiple
centers at the FDA without a single authoritative agency voice on the issue. This has led
to inter-center inconsistencies in interpretation and application of regulations, data
requirements, and the content of potentially relevant guidance documents. There
appears to be uncertainty at times about whether a probiotic product should be
regulated by the Center for Food Safety and Applied Nutrition, the Center for Biologic
Evaluation and Research or the Center for Drug Evaluation and Research.
Apart from classification uncertainty, regulatory approaches developed for other
products may not be a good fit for probiotics or may need to take into account some of
the unique features of probiotics. By their very nature, probiotics are live organisms that
are dynamic and unlike chemicals. Probiotics are also likely to lose viability and degrade
under certain circumstances. Probiotic research and manufacturing involve
consideration of variables such as the effect of the environment on the viability and
effectiveness of the probiotics and the interaction between the human body’s biology
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and biochemistry and the human microbiome, including factors within the human body
that may activate or deactivate the probiotics. Without stringent manufacturing
procedures and quality controls, specific probiotics may lose the properties that once
formed their isolation and selection criteria (13). Animal models may be of limited
utility because of the significant differences between human and animal microbiomes
and immune systems. Finally, many probiotics are consumed by individuals on a daily
basis as foods making dosing of probiotics for therapeutic purposes challenging.
An example of the questionable fit between traditional regulatory concerns and
probiotics is a 2010 FDA guidance document that sets forth requirements for chemistry,
manufacturing, and controls for early clinical trials using live biotherapeutic products
(LBP) (14). Without using the word “probiotic”, the guidance and its definition of LBP
appear to include probiotics intended to be used as drugs (15). As written, the
requirements are not adequately customized for probiotics. Specifically, the current LBP
guidance requires a summary of the phenotype or genotype of the strain with specific
attention to the genetic loci that may indicate activity or potency. It is very difficult to
pinpoint the genetic loci for probiotics, especially in early clinical trials. Furthermore, the
guidance refers to genotypic methods that are inadequate and outdated. Given the
reduction in their costs, current genome sequencing technology should be required.
Moreover, LBP characterization standards are focused on the product; this may be
inappropriate for probiotics because safety and effectiveness may be dependent on
both the characteristics of the product and the microbiome of the consumer.
While probiotics do have some distinctive characteristics, they arguably are not unique
enough to warrant their own regulatory pathway, in large part because probiotic
products are so varied, potentially being marketed as foods, dietary supplements,
medical foods, foods for special dietary use, or drugs. Two changes in the current
regulatory framework, however, could improve how probiotics are addressed by FDA.
The HMP is driving studies by academic researchers of probiotic products traditionally
sold as foods or dietary supplements to determine whether certain therapeutic claims
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are, or could be, valid. Under the current regulatory framework, if the intent of the
study is to substantiate a drug claim (a claim that a substance can diagnose, cure,
mitigate, treat or prevent disease), researchers are required to submit an Investigational
New Drug Application (IND). The IND may include results of pharmacologic and toxicity
studies; chemistry, manufacturing and controls data as well as a clinical plan. It also
generally includes three phases of human studies for the development of the new drug
product. This means that researchers attempting to establish, for example, that a yogurt
currently available on supermarket shelves reduced the incidence of diarrhea in the
elderly, would be subject to the expansive full drug approval process, including phase 1
clinical safety studies. In some cases, the high costs of the IND have been an obstacle to
such research.
While we agree that probiotic products that wish to make therapeutic claims generally
should be subject to the same rigorous requirements as other products making drug
claims, including adequate and well-controlled investigations supporting such claims,
under limited circumstances we recommend an abbreviated IND process for some
probiotic products, allowing them to bypass Phase 1 clinical safety studies. Probiotics
that would be eligible for an abbreviated IND process are probiotic foods, dietary
supplements, and dietary ingredients for which there is adequate evidence of safety in
the target population; approved food additives; and substances generally recognized as
safe (GRAS).
The probiotic that is the subject of the abbreviated IND would be required to be studied
in essentially the same dose (or amount) and delivery system as the probiotic previously
deemed to be safe, so as not to raise safety concerns. Under the abbreviated IND
process, if the sponsor wished to conduct a study to support a therapeutic benefit for an
at-risk population, such as premature infants, FDA would need to make a determination
as to whether the available information on safety is suitable for this new target
population. The abbreviated IND would provide a mechanism for products currently in
the food and dietary supplement category to make drug claims by moving into the drug
category, albeit with a slightly less burdensome IND process.
5

A second recommendation targets the regulation of unsubstantiated claims. Probiotic
claims are currently regulated by both FDA and the FTC. FDA regulates advertising
claims for prescription drugs and labeling claims for essentially all FDA regulated
products, including prescription and over the counter (OTC) drugs, dietary supplements,
medical devices, cosmetics and food. FTC regulates advertising claims for OTC drugs,
foods, dietary supplements, medical devices and cosmetics. FDA regulation of claims
differs based on which category a product falls within. Drug claims or health claims, i.e.,
claims of a reduction of risk of disease, require FDA approval prior to marketing. Foods
and dietary supplements, however, may make structure/function claims without
premarket approval, thus presenting an opportunity for misleading and unsubstantiated
claims. Such claims describe the role of a nutrient or dietary ingredient intended to
affect normal structure or function of the body in humans. The manufacturer is
responsible for ensuring the accuracy and truthfulness of these claims. Often these
claims are vague and difficult to understand.
In addition to providing an opportunity for making unsubstantiated claims,
structure/function claims may be difficult to substantiate. For example, a number of
probiotics make claims that they maintain or promote a healthy “balance” of microorganisms in the body (often in the digestive system). This concept of promoting
“balance” is not part of the disease-focused paradigm that has governed regulation of
health-related products in the U.S., in large part because of a paucity of measurable
outcomes to determine balance and whether such “balance” is beneficial. Some
authors, however, have suggested conceptual approaches to the measurement of
balance. For example, Sanders et. al. have proposed the concept of homeostasis as a
focus of health studies and provide a rationale based on solid statistical theory as a way
to measure wellness or health maintenance (16). Yet, much more scientific work needs
to be done before such a concept can be implemented, including identifying appropriate
biomarkers for study.
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The existence of unsubstantiated claims in the marketplace is due in part to lack of
agency enforcement resources but also to the difficulty of policing advertising on the
Internet and to the lure of profit by potential probiotic manufacturers. In order to
address the problem, in addition to greater enforcement efforts, we recommend that
FDA establish a monograph for probiotic foods and dietary supplements similar to that
adopted in Canada for natural health products. Unlike the U.S., Canada has taken a
proactive role in regulating probiotic products. Most probiotic products that would be
considered dietary supplements in the United States are regulated in Canada as natural
health products and fall under probiotics and live micro-organisms monographs (17)—a
set of requirements that cover acceptable ingredients, doses, formulations, quality
specifications and labeling/claims. Under Health Canada’s probiotics monograph, all
probiotic natural health products require pre-market assessment and licensing and must
be supported by evidence of strain-specific safety and efficacy under recommended
conditions of use. Compliance with the monograph requirements leads to expedited
review of the application for marketing the product. The Canadian probiotics
monograph allows four specific claims for four specific strains of live microorganisms
and limited generalized claims for combinations of strains that meet all additional
requirements. (See Table 2.) Natural health products are not limited to these claims;
however additional evidence supporting the product’s safety and efficacy is required for
claims not specified by the monographs. (See Figure 1.)
FDA could create probiotics monographs for those strains it believes are generally
recognized as safe and effective for a particular benefit and could utilize expert panels
as it did in the development of the OTC drug monographs. Similar to the FDA
monographs for most OTC drug products, a probiotics monograph would include a list of
active ingredients found to have achieved a specified benefit; levels of active ingredients
needed to achieve the benefit; product claims that the FDA believes fairly communicate
that benefit; mandatory warnings for this category of products; purity standards for
active ingredients; a listing of permissible excipient and/or inactive ingredients; and
methods and standards of testing. Ideally, a monograph would reduce the number of
7

structure/function, and arguably unsubstantiated, claims that could be made about
probiotic products and thereby help the consumer make more informed decisions when
purchasing these products.
Adoption of the abbreviated IND and monograph procedures would provide more
balance in the regulation of probiotic products, leading to more reliable quality
standards and properly substantiated efficacy claims that better reflect the nature of
probiotics.
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Table 1. FDA Product Categories and Regulating Centers for Probiotics for Human Use
Product
Category

Dietary
Supplements

Cosmetics

Drugs

Biologics

Medical Devices

Included in All food
products
category
including
bottled
water, food
additives,
infant
formula,
medical
foods, and
foods for
special
dietary use.

Vitamins,
minerals, herbs
or other
botanicals,
amino acids,
or dietary
substances
used to
supplement
the diet by
increasing the
total dietary
intake; or a
concentrate,
metabolite,
constituent or
extract of the
above

Products
used to
cleanse or
beautify the
body.

Over the
counter and
prescription
drugs.

Vaccines,
blood
products,
and other
biologics.

Instruments, machines,
or other articles which
do not achieve their
primary intended
purposes through
chemical action within
the body. This
encompasses electronic
products including any
product that gives off
radiation.

Regulating Center for
Food Safety
Center
and Applied
Nutrition
(CFSAN)

Center for
Food Safety
and Applied
Nutrition
(CFSAN)

Center for
Food Safety
and Applied
Nutrition
(CFSAN)

Center for
Drug
Evaluation
and
Research
(CDER)

Center for
Biologics
Evaluation
and
Research
(CBER)

Center for Devices and
Radiological Health
(CDRH)

Foods
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Table 2. Probiotic product claims allowed by Health Canada probiotics monograph
Microorganism
•

Lactobacillus johnsonii La1

•

L. johnsonii Lj1

•

L. johnsonii NCC 533

•

Lactobacillus rhamnosus
GG

•

Saccharomyces boulardii

Eligible Specific Claims
An adjunct to physician-supervised antibiotic therapy in patients with Helicobacter
pylori infections

•

Helps to manage acute infectious diarrhea.

•

Helps to manage antibiotic-associated diarrhea.

•

Helps to reduce the risk of antibiotic-associated diarrhea

Helps to reduce the risk of antibiotic-associated diarrhea
Eligible General Claims

•

Lactobacillus johnsonii La1

•

Probiotic that forms part of a natural healthy gut flora.

•

L. johnsonii Lj1

•

Provides live microorganisms that form part of a natural healthy gut flora.

•

L. johnsonii NCC 533

•

Probiotic that contributes to a natural healthy gut flora.

•

Lactobacillus rhamnosus
GG

•

Provides live microorganisms that contribute to a natural healthy gut flora.

•

Saccharomyces boulardii

•

Probiotic to benefit health and/or to confer a health benefit.

•

Lactobacillus johnsonii La1

•

•

L. johnsonii Lj1

Provides live microorganisms to benefit health and/or to confer a health
benefit.

•

L. johnsonii NCC 533

•

Lactobacillus rhamnosus
GG
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